Drugs / ADV/IL-12
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04911166 | Oct 2021 → Aug 2024 | non-small cell lung carcinoma | The Methodist Hospital Research Institute | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADV/IL-12 | “The starting dose of ADV/IL-12 will be 5 × 1011 vp.” NCT04911166 ↗ |
| Route | Other | “ADV/IL-12 will be intratumorally injected on Day 0 of the study” NCT04911166 ↗ |